Literature DB >> 25176168

Interaction between the cholecystokinin and endogenous cannabinoid systems in cued fear expression and extinction retention.

Mallory E Bowers1, Kerry J Ressler2.   

Abstract

Post-traumatic stress disorder (PTSD) is thought to develop, in part, from improper inhibition of fear. Accordingly, one of the most effective treatment strategies for PTSD is exposure-based psychotherapy. Ideally, neuroscience would inform adjunct therapies that target the neurotransmitter systems involved in extinction processes. Separate studies have implicated the cholecystokinin (CCK) and endocannabinoid systems in fear; however, there is a high degree of anatomical colocalization between the cannabinoid 1 receptor (Cnr1) and CCK in the basolateral amygdala (BLA), a brain region critical for emotion regulation. Although most research has focused on GABA and GABAergic plasticity as the mechanism by which Cnr1 mediates fear inhibition, we hypothesize that a functional interaction between Cnr1 and CCKB receptor (CCKBR) is critical for fear extinction processes. In this study, systemic pharmacological manipulation of the cannabinoid system modulated cued fear expression in C57BL/6J mice after consolidation of auditory fear conditioning. Knockout of the CCKBR, however, had no effect on fear- or anxiety-like behaviors. Nonetheless, administration of a Cnr1 antagonist increased freezing behavior during a cued fear expression test in wild-type subjects, but had no effect on freezing behavior in CCKBR knockout littermates. In addition, we found that Cnr1-positive fibers form perisomatic clusters around CCKBR-positive cell bodies in the BLA. These CCKBR-positive cells comprise a molecularly heterogenous population of excitatory and inhibitory neurons. These findings provide novel evidence that Cnr1 contributes to cued fear expression via an interaction with the CCK system. Dysfunctional Cnr1-CCKBR interactions might contribute to the etiology of, or result from, fear-related psychiatric disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25176168      PMCID: PMC4289957          DOI: 10.1038/npp.2014.225

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  97 in total

Review 1.  Emotion circuits in the brain.

Authors:  J E LeDoux
Journal:  Annu Rev Neurosci       Date:  2000       Impact factor: 12.449

2.  Localization of the CB1 type cannabinoid receptor in the rat basolateral amygdala: high concentrations in a subpopulation of cholecystokinin-containing interneurons.

Authors:  A J McDonald; F Mascagni
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

3.  Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations.

Authors:  N Hájos; I Katona; S S Naiem; K MacKie; C Ledent; I Mody; T F Freund
Journal:  Eur J Neurosci       Date:  2000-09       Impact factor: 3.386

4.  Suppression of conditioned fear by administration of CCKB receptor antagonist PD135158.

Authors:  T Tsutsumi; J Akiyoshi; K Isogawa; Y Kohno; T Hikichi; H Nagayama
Journal:  Neuropeptides       Date:  1999-12       Impact factor: 3.286

Review 5.  Pharmacology of cannabinoid CB1 and CB2 receptors.

Authors:  R G Pertwee
Journal:  Pharmacol Ther       Date:  1997       Impact factor: 12.310

6.  Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission.

Authors:  I Katona; E A Rancz; L Acsady; C Ledent; K Mackie; N Hajos; T F Freund
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

7.  Activation of CB1 cannabinoid receptors in rat hippocampal slices inhibits potassium-evoked cholecystokinin release, a possible mechanism contributing to the spatial memory defects produced by cannabinoids.

Authors:  M C Beinfeld; K Connolly
Journal:  Neurosci Lett       Date:  2001-03-23       Impact factor: 3.046

Review 8.  Modulation of transmitter release via presynaptic cannabinoid receptors.

Authors:  E Schlicker; M Kathmann
Journal:  Trends Pharmacol Sci       Date:  2001-11       Impact factor: 14.819

9.  Behavioral and endocrine response to cholecystokinin tetrapeptide in patients with posttraumatic stress disorder.

Authors:  M Kellner; K Wiedemann; A Yassouridis; R Levengood; L S Guo; F Holsboer; R Yehuda
Journal:  Biol Psychiatry       Date:  2000-01-15       Impact factor: 13.382

10.  Mitogenic effect of gastrin and expression of gastrin receptors in duct-like cells of rat pancreas.

Authors:  I Rooman; J Lardon; D Flamez; F Schuit; L Bouwens
Journal:  Gastroenterology       Date:  2001-10       Impact factor: 22.682

View more
  20 in total

1.  Endocannabinoid signaling within the basolateral amygdala integrates multiple stress hormone effects on memory consolidation.

Authors:  Piray Atsak; Daniela Hauer; Patrizia Campolongo; Gustav Schelling; Raquel V Fornari; Benno Roozendaal
Journal:  Neuropsychopharmacology       Date:  2014-12-30       Impact factor: 7.853

Review 2.  Sex differences in fear extinction.

Authors:  E R Velasco; A Florido; M R Milad; R Andero
Journal:  Neurosci Biobehav Rev       Date:  2019-05-23       Impact factor: 8.989

3.  Functional neuroanatomy of the basolateral amygdala: Neurons, neurotransmitters, and circuits.

Authors:  Alexander J McDonald
Journal:  Handb Behav Neurosci       Date:  2020-03-31

Review 4.  Toward a translational approach to targeting the endocannabinoid system in posttraumatic stress disorder: a critical review of preclinical research.

Authors:  Santiago Papini; Gregory M Sullivan; Denise A Hien; Erel Shvil; Yuval Neria
Journal:  Biol Psychol       Date:  2014-11-04       Impact factor: 3.251

Review 5.  Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders.

Authors:  N Singewald; C Schmuckermair; N Whittle; A Holmes; K J Ressler
Journal:  Pharmacol Ther       Date:  2014-12-27       Impact factor: 12.310

6.  Cholecystokinin immunoreactive neurons in the basolateral amygdala of the rhesus monkey (Macaca mulatta).

Authors:  Alexander J McDonald; Franco Mascagni
Journal:  J Comp Neurol       Date:  2019-04-22       Impact factor: 3.215

Review 7.  Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder.

Authors:  Matthew N Hill; Patrizia Campolongo; Rachel Yehuda; Sachin Patel
Journal:  Neuropsychopharmacology       Date:  2017-07-26       Impact factor: 7.853

Review 8.  An Overview of Translationally Informed Treatments for Posttraumatic Stress Disorder: Animal Models of Pavlovian Fear Conditioning to Human Clinical Trials.

Authors:  Mallory E Bowers; Kerry J Ressler
Journal:  Biol Psychiatry       Date:  2015-06-15       Impact factor: 13.382

9.  Enhancing Endocannabinoid Neurotransmission Augments The Efficacy of Extinction Training and Ameliorates Traumatic Stress-Induced Behavioral Alterations in Rats.

Authors:  Maria Morena; Andrea Berardi; Paola Colucci; Maura Palmery; Viviana Trezza; Matthew N Hill; Patrizia Campolongo
Journal:  Neuropsychopharmacology       Date:  2017-12-21       Impact factor: 7.853

Review 10.  The endocannabinoid system in guarding against fear, anxiety and stress.

Authors:  Beat Lutz; Giovanni Marsicano; Rafael Maldonado; Cecilia J Hillard
Journal:  Nat Rev Neurosci       Date:  2015-12       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.